Impact of delayed initiation of erythropoietin in critically ill patients
2007

Impact of Delayed Erythropoietin Use in Critically Ill Patients

Sample size: 126 publication Evidence: moderate

Author Information

Author(s): Duby Jeremiah J, Erstad Brian L, Abarca Jacob, Camamo James M, Huckleberry Yvonne, Bramblett Stuart N

Primary Institution: Kaiser Permanente

Hypothesis

What is the impact of delayed initiation of recombinant human erythropoietin (rHuEPO) for anemia of critical illness?

Conclusion

Delayed initiation of rHuEPO for anemia of critical illness resulted in comparable hemoglobin and transfusion benefits.

Supporting Evidence

  • Eighty percent of patients were transfused with an average total of 5.42 units received.
  • RBC exposure inversely correlated with a lower mean hemoglobin response to rHuEPO.
  • The average change in hemoglobin from baseline to 28 days after starting rHuEPO was similar to that found in the RCT.

Takeaway

This study looked at how starting a treatment called erythropoietin later affects patients in the ICU who have low blood levels. It found that starting it later still helps with their blood levels and need for blood transfusions.

Methodology

Retrospective medical record review of patients treated with rHuEPO for anemia of critical illness.

Potential Biases

Efforts were made to reduce potential bias and inaccuracy, but retrospective design may introduce bias.

Limitations

The study was retrospective and lacked a control group.

Participant Demographics

Average age was 56.5 years; patients were admitted to medical or surgical ICUs.

Statistical Information

P-Value

p < 0.0001

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1186/1471-2326-7-1

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication